FIELD: medicine.
SUBSTANCE: invention relates to treatment of cerebral diseases. Disclosed is the use of a ligand-bound gold cluster for treating cerebral stroke in a subject, where the gold cluster bound to the ligand includes a gold nucleus and a ligand bound to the gold nucleus, wherein cerebral stroke is selected from the group consisting of cerebral hemorrhagic stroke and transient ischemic attack (TIA); gold core has a diameter in range of 0.5–3 nm; ligand is one selected from a group consisting of L-cysteine and derivatives thereof, D-cysteine and derivatives thereof, cysteine-containing oligopeptides and derivatives thereof, and other thiol-containing compounds; L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC) and N-acetyl-L-cysteine (L-NAC), and where D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC) and N-acetyl-D-cysteine (D-NAC); cysteine-containing oligopeptides and derivatives thereof are cysteine-containing dipeptides, cysteine-containing tripeptides, cysteine-containing tetrapeptides or cysteine-containing pentapeptides; and wherein the other thiol-containing compounds are selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, dodecyl mercaptan, 2-aminoethane thiol (CSH), 3-mercaptopropionic acid (MPA) and 4-mercaptobenic acid (p-MBA).
EFFECT: invention provides developing a drug capable of treating patients with cerebral stroke.
6 cl, 26 dwg, 1 tbl, 4 ex
